Amedisys (AMED) 8-K Regulation FD Disclosure

Investor Presentation

Leading Home Health Care & Hospice

September 2011

Exhibit 99.1

Leading Home Health & Hospice

Forward-looking statements

This presentation may include forward-looking statements as defined by the

Private Securities Litigation Reform Act of 1995. These forward-looking

statements are based upon current expectations and assumptions about our

business that are subject to a variety of risks and uncertainties that could cause

actual

results

to

differ

materially

from

those

described

in

this

presentation.

You

should not rely on forward-looking statements as a prediction of future events.

Additional

information

regarding

factors

that

could

cause

actual

results

to

differ

materially from those discussed in any forward-looking statements are described

in reports and registration statements we file with the SEC, including our Annual

Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and

Current Reports on Form 8-K, copies of which are available on the Amedisys

internet

website

http://www.amedisys.com

or

by

contacting

the

Amedisys

Investor

Relations department at (800) 467-2662.

We disclaim any obligation to update any forward-looking statements or any

changes in events, conditions or circumstances upon which any forward-looking

statement may be based except as required by law.

2

www.amedisys.com

NASDAQ: AMED

We encourage everyone to visit the

Investors Section of our website at

www.amedisys.com, where we

have posted additional important

information such as press releases,

profiles concerning our business

and clinical operations and control

processes, and SEC filings.

We intend to use our website to

expedite public access to time-

critical information regarding the

Company in advance of or in lieu of

distributing a press release or a

filing with the SEC disclosing the

same information.

Leading Home Health & Hospice

Company overview

1

3

•

Founded in 1982, publicly listed 1994

•

575 locations in 45 states

•

Leading provider of home health services

-

Services include skilled nursing and therapy

services

•

Growing hospice business

•

94% of Home Health revenue is episodic

based (both Medicare & non-Medicare)

17,000 employees

Home Health Division:

-Total admits. and recerts. in 2Q11 ~ 118,000

-8.5 million visits run rate in 2011

Hospice Division:

-

Average daily census = 3,784

-

Average length of stay = 86 days

2011 revenue guidance = $1.475 -

$1.5 billion

2

1

For the quarter ended June 30, 2011

2

Provided

as

of

the

date

of

our

Form

8-K

filed

with

the

Securities

and

Exchange

Commission

on

August

2,

2011.

Stats

Revenue Mix

13%

Home Health

Hospice

87%

Leading Home Health & Hospice

Management team

William F. Borne, Chairman and CEO

Founder and CEO since 1982

29 years leading the industry

Michael D. Snow, Chief Operating Officer

31 years leading health care operations

Wellmont, HealthSouth, HCA

Tim Barfield, Chief Development Officer

16 years of corporate development experience

Gov. Bobby Jindal , Vinson & Elkins, The Shaw Group

Dale E. Redman, CPA, Chief Financial Officer

35 years of senior level financial experience

Winward Capital, United Companies Financial

4

Jeffrey D. Jeter, Chief Compliance Officer

15 years of health care law and compliance expertise

Former Medicaid prosecutor,  LA AG for DOJ

Michael O. Fleming, Chief Medical Officer

29 years as a family physician

Former President of AAFP, first industry CMO

G. Patrick Thompson, Chief Information Officer

24 years of corporate administration experience

Arthur Andersen, Turner Industries, The Shaw Group

David R. Bucey, General Counsel

25 years of experience in corporate law

Coca-Cola Company, McKenna Long & Aldridge

Leading Home Health & Hospice

Agency Locations

5

485 -

Home Health locations

90 -

Hospice locations

*As of June 30, 2011

Leading Home Health & Hospice

Home Health Division

6

•

Industry leader

–

Strong national footprint –

485 locations across 45 states as of June 30, 2011

–

$326 million revenue in 2Q 2011

•

Strong clinical quality

•

Experienced divisional leadership

•

World-class technology platform

•

Well positioned to capitalize

on organic and consolidation

opportunities

$1,118

$1,409

$1,493

$388

$326

$-

$200

$400

$600

$800

$1,000

$1,200

$1,400

$1,600

2008

2009

2010

2Q 2010

2Q 2011

Home Health Revenue

Leading Home Health & Hospice

Hospice Division

7

•

90 locations across 25 states as of June 30, 2011

–

$47 million revenue in 2Q 2011

•

Operational efficiencies drive strong margins

•

Quality care drives referral growth

•

Partnered with the country’s largest and leading Home Health company

–

Offering comprehensive

continuum of at-home care

–

Collective resources to drive

operational and clinical

excellence

–

Cross referral opportunities

to drive growth

$69

$104

$141

$34

$47

$-

$20

$40

$60

$80

$100

$120

$140

$160

2008

2009

2010

2Q 2010

2Q 2011

Hospice Revenue

Leading Home Health & Hospice

Medicare market size

8

Source: Congressional Budget Office baseline reports (Home health figures from 2010 report, Hospice figures from 2009 report)

2009-2019

CAGR

Home Health

9.35%

Hospice

5.40%

$18

$20

$21

$23

$25

$28

$31

$33

$37

$40

$44

$13

$13

$14

$15

$15

$16

$17

$18

$19

$20

$22

$-

$10

$20

$30

$40

$50

$60

$70

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

Medicare Reimbursement

Home Health

Hospice

Leading Home Health & Hospice

Value Proposition

•

Home Health is the lowest total cost, lowest daily cost, and provides care

over the longest period of time

9

*Source: National Association for Home Health & Hospice, Medpac June 2010 Data Book

Hospital

SNF

Home Health

Average Cost of Stay

$28,191

$14,688

$5,293

Average Length of Stay

4.9 days

27 days

106 days

Per Diem Cost

$5,765

$544

$50

Our Long Term Operating Tenets

10

Leading Home Health & Hospice

Clinical

Excellence

Growth

Efficiency

Leading Home Health & Hospice

Focus on Clinical Outcomes

Amedisys vs. Footprint –

Outcomes March 2011

•

Exceeded or met 8 out of 8 outcomes vs. footprint of reported measures

*

Lower % is better         

Source:  Medicare

11

58

52

67

69

70

90

53

28

52

51

61

64

58

88

43

28

0

10

20

30

40

50

60

70

80

90

100

Amedisys

Footprint

Impovement in

Ambulation

Improvement in

Transferring

Improvement in

Bathing

Improvement in

Pain

Breathing

Improvement

Improvement of

Surgical Wounds

Improvement in

Mgmt of Oral

Meds

Acute Care

Hospitalization*

Growth

Efficiency

Clinical

Excellence

Leading Home Health & Hospice

Quality Care Initiatives

12

Leading Home Health & Hospice

Improve Patient

Outcome –

Reduce ER &

Hospitalization

Encore/

Telehealth

Nurse

Practitioners

Advanced

Chronic

Care Mgmt.

Evidence

based Best

Practices

Care

Transitions

Care Team

Conference

Growth

Efficiency

Clinical

Excellence

-

Leading Home Health & Hospice

Growth -

Organic

13

Tactical growth initiatives

•

Care center action plans

•

Heightened focus on low

performers

•

Leading indicators

•

Measure effectiveness

•

New regional leadership

•

Training & development

•

CRM tool / market intel

•

Incentive alignment

Growth

Efficiency

Excellence

Same store episodic-based admission growth is the percent increase in our same store episodic-based admissions for the period as a percent of the same store episodic-based admissions of the      

   prior period.

Clinical

3%

6%

-4%

15%

12%

17%

-10%

-5%

0%

5%

10%

15%

20%

2009

2010

2Q 2011

Same Store Episodic-Based

Admission Growth

1

Home Health

Hospice

Leading Home Health & Hospice

Growth -

External

Industry Consolidation

–

11,400 home health

provider numbers

1

–

3,400 hospice provider

numbers

1

–

12-15% public company

market share

2

Focus

–

CON markets

–

Geographic expansion

–

Market penetration

–

Hospital JV’s

Continuum of

Care

Traditional Investments

Complementary Investments

–

Care management capabilities

–

Revenue diversification

–

Disease Management

14

1

Source: MedPac June 2011 data book

2

Source: CBO, NHE and public company 10-K’s

Growth

Clinical

Excellence

Efficiency

Leading Home Health & Hospice

Beacon Acquisition

•

Premier hospice in Northeast

–

23 locations

–

$80 million in revenue

–

Quality provider

–

Strong leadership and operations

Beacon Hospice Care Centers

Amedisys Hospice Care Centers

Amedisys Home Health Care Centers

15

Efficiency

Clinical

Excellence

Growth

Leading Home Health & Hospice

Efficiency –

Systems Infrastructure

16

Efficiency

Clinical

Excellence

Growth

•

Untethers

clinical staff

from bricks +

mortar

•

Accuracy

•

Completeness

•

At the bedside

•

F2F

•

Peoplesoft

•

Current/ future

growth

•

Proprietary

•

Home Care

design

•

F2F

AMS

ERP

System

Field

refresh

Point-

of-care

Leading Home Health & Hospice

Industry Challenges/Opportunities

17

Challenges

Opportunities

•

F2F

•

Therapy reassessment

•

2012 and future

reimbursement /rebasing

•

Regulatory focus

•

Demographics

•

Low cost setting

•

Quality differentiation

•

Value based pricing

•

Consolidation

•

Health care reform

•

Near-term hospice reimbursement

stability

Future state

•

Educating payors, policy

makers and health systems on

the value of a continuum

model

•

Regulatory inefficiencies

•

Risk sharing/capitation

•

Seamless patient care

•

ACO’s / Medical home

•

System savings

Leading Home Health & Hospice

Investment Rationale

•

Solid industry growth rate

•

IT leader

•

Clinical quality and innovation

•

Low cost setting in high cost healthcare industry

•

Scalable infrastructure

•

Expected industry consolidation

•

Strong liquidity and capital position

18

Tremendous

Opportunities

Leading Home Health & Hospice

Financial Review

19

Leading Home Health & Hospice

Financial highlights

20

$-

$1.00

$2.00

$3.00

$4.00

$5.00

$6.00

$-

$200

$400

$600

$800

$1,000

$1,200

$1,400

$1,600

$1,800

2004

2005

2006

2007

2008

2009

2010

2011

Revenue

Projected Revenue

EPS

Projected EPS

Leading Home Health & Hospice

21

Summary financial results

($ in millions, except per share data and

DSO)

2009

2010

2Q10

2Q11

Net revenue

$1,513.5

$1,634.3

$422.3

$373.7

Gross margin

789.0

813.9

213.1

180.6

CFFO

247.7

206.3

54.4

24.0

Adjusted EBITDA

1

261.8

242.0

64.6

44.1

Adjusted Fully-diluted EPS

2

$4.89

$4.29

$1.15

$0.67

Days Sales Outstanding

33.9

32.8

32.5

36.0

1

Adjusted EBITDA is defined as net income attributable to Amedisys, Inc. before provision for income taxes, net interest (income) expense, and depreciation

and amortization plus certain adjustments (i.e Certain items incurred in 2010  and 2011 which are detailed in our Form 8-K filed with the Securities and

Exchange Commission on February 22, 2011 and August 2, 2011, respectively). Adjusted EBITDA should not be considered as an alternative to, or more

meaningful than, income before income taxes, cash flow from operating activities, or other traditional indicators of operating performance. This calculation of

adjusted EBITDA may not be comparable to a similarly titled measure reported by other companies, since not all companies calculate this non-GAAP financial

measure in the same manner.

2

Adjusted diluted earnings per share is defined as diluted earnings per share plus the earnings per share effect of certain adjustments (i.e. Certain items

incurred in 2010  and 2011 which are detailed in our Form 8-K filed with the Securities and Exchange Commission on February 22, 2011 and August 2, 2011,

respectively).  Adjusted diluted earnings per share should not be considered as an alternative to, or more meaningful than, income before income taxes, cash

flow from operating activities, or other traditional indicators of operating performance. This calculation of adjusted diluted earnings per share may not be

comparable to a similarly titled measure reported by other companies, since not all companies calculate this non-GAAP financial measure in the same manner.

Leading Home Health & Hospice

22

Summary performance results

2009

2010

2Q10

2Q11

Home Health

Agencies at period end

521

486

529

485

Total visits

8,702,146

9,065,549

2,320,736

2,136,806

Episodic-based admissions

231,782

253,763

63,076

58,980

Episodic-based completed

episodes

411,975

424,988

109,420

101,146

Episodic-based revenue per

episode

$3,166

$3,311

$3,372

$3,034

Hospice

Agencies at period end

65

67

72

90

Total admissions

9,002

11,510

2,874

3,740

Hospice days

784,577

1,051,209

258,172

344,353

Daily census

2,150

2,880

2,837

3,784

Average length of stay

82

87

87

86

Leading Home Health & Hospice

23

Summary balance sheet

Dec. 31, 2010

Jun. 30, 2011

Assets

Cash

$      120.3

$         28.1

Accounts Receivable, Net

141.5

153.3

Property and Equipment

138.6

144.4

Goodwill

791.4

901.6

Other

108.1

113.2

Total Assets

$   1,299.9

$    1,340.6

Liabilities and Equity

Debt

$      181.9

$       163.3

All Other Liabilities

238.3

247.3

Equity

879.7

930.0

Total Liabilities and Equity

$  1,299.9

$    1,340.6

Leverage Ratio, Net of Cash

0.3x

0.4x

Leading Home Health & Hospice

24

Liquidity

•

Cash balance at 6/30/11 =  $28M

•

Available line of credit (LOC): 6/30/11 =  $231M

•

2011

Estimated

CFFO

-

Cap

Ex

=

$90M

-

$100M

Leading Home Health & Hospice

25

Guidance

1

Calendar Year 2011

2

Net revenue:

$1.475 -

$1.5 billion

EPS:

$2.20 -

$2.40

Diluted shares:

29.3 million

1

Guidance includes the effects of  our recently announced Beacon acquisition but excludes the effects of the following:  any future acquisitions, if any are made;

effects of any share repurchases; non-recurring costs that may be incurred during the year; or the impact of the final 2012 Medicare rate changes.

2

Provided as of the date of our Form 8-K filed with the Securities and Exchange Commission on August 2, 2011.

Leading Home Health & Hospice

Summary

26

Tremendous

Opportunities

•

Solid industry growth rate

•

IT leader

•

Clinical quality and innovation

•

Low cost setting in high cost healthcare industry

•

Scalable infrastructure

•

Expected industry consolidation

•

Strong liquidity and capital position

Leading Home Health & Hospice

Contact information

Kevin B. LeBlanc

Director of Investor Relations

Amedisys, Inc.

5959 S. Sherwood Forest Boulevard

Baton Rouge, LA 70816

Office: 225.299.3391

Fax: 225.298.6435

kevin.leblanc@amedisys.com

27